Novel targets for the treatment and palliation of gastrointestinal neuroendocrine tumors

Current Opinion in Investigational Drugs

Volumn 9, Issue 6, 2008, Pages 576-582

  Pinchot, S N ^a   Pitt, S C ^a   Sippel, R S ^a   Kunnimalaiyaan, M ^a   Chen, H ^a  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

Carcinoid; Glycogen synthase kinase 3 ; Histone deacetylase inhibitor; Lithium; Neuroendocrine; Phosphatidylinositol 3 kinase Akt signaling pathway; ZM 336372

Indexed keywords

1 AZAKENPAULLONE; 2 (2,4 DICHLOROPHENYL) 3 (1 METHYL 3 INDOLYL)MALEIMIDE; 2 (3 CHLORO 4 HYDROXYANILINO) 3 (2 NITROPHENYL)MALEIMIDE; 2 MORPHOLINO 8 PHENYLCHROMONE; ANGIOGENESIS INHIBITOR; BAG 956; BEVACIZUMAB; CHIR 99021; CYCLIN D1; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; EVEROLIMUS; GEFITINIB; GLYCOGEN SYNTHASE KINASE 3 INHIBITOR; GLYCOGEN SYNTHASE KINASE 3BETA; HISTONE DEACETYLASE INHIBITOR; LITHIUM CARBONATE; MITOGEN ACTIVATED PROTEIN KINASE 3; MYC PROTEIN; N [5 (3 DIMETHYLAMINOBENZAMIDO) 2 METHYLPHENYL] 4 HYDROXYBENZAMIDE; PROTEIN BCL 2; PROTEIN C JUN; SORAFENIB; SUBEROYL BIS HYDROXAMIC ACID; SUNITINIB; TEMSIROLIMUS; TRICIRIBINE; TRICIRIBINE PHOSPHATE; VALPROATE SEMISODIUM; VALPROIC ACID; VATALANIB; VD 0002; WORTMANNIN;

APOPTOSIS; BIPOLAR DISORDER; CANCER INHIBITION; CANCER PALLIATIVE THERAPY; CARCINOGENESIS; CARCINOID; CARCINOID SYNDROME; CELL DEATH; CHROMOSOME 18Q; CONCENTRATION RESPONSE; DEPRESSION; DOWN REGULATION; DRUG MECHANISM; DRUG TARGETING; ENZYME ACTIVATION; GASTROINTESTINAL TUMOR; GENE OVEREXPRESSION; HEMATOLOGIC MALIGNANCY; HUMAN; METASTASIS; MOLECULAR DYNAMICS; MULTIPLE ENDOCRINE NEOPLASIA; NEUROENDOCRINE TUMOR; NONHUMAN; PHEOCHROMOCYTOMA; REVIEW; SCHIZOPHRENIA; SIGNAL TRANSDUCTION;

ANTINEOPLASTIC AGENTS; GASTROINTESTINAL NEOPLASMS; HUMANS; NEUROENDOCRINE TUMORS; PALLIATIVE CARE; SIGNAL TRANSDUCTION;

EID: 44649192685     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (45)

1. Modlin IM, Lye KD, Kidd M: A five-decade analysis of 13,715 carcinoid tumors. Cancer (2003) 97(4):934-959. • This compilation of several large US-based databases comprising data from patients between 1950 to 1999 examined 13,715 carcinoid tumors and provided epidemiological information regarding the natural history and evolution of the detection and diagnosis of carcinoid disease.
2. Chen H, Hardacre JM, Uzar A, Cameron JL, Choti MA: Isolated liver metastases from neuroendocrine tumors: Does resection prolong survival? J Am Coll Surg (1998) 187(1):88-92.
3. Touzios JG, Kiely JM, Pitt SC, Rilling WS, Quebbeman EJ, Wilson SD, Pitt HA: Neuroendocrine hepatic metastases: Does aggressive management improve survival? Ann Surg (2005) 241(5):776-783.
4. Musunuru S, Chen H, Rajpal S, Stephani N, McDermott JC, Holen K, Rikkers LF, Weber SM: Metastatic neuroendocrine hepatic tumors: Resection improves survival. Arch Surg (2006) 141(10):1000-1004.
5. Van Gompel JJ, Sippel RS, Warner TF, Chen H: Gastrointestinal carcinoid tumors: Factors that predict outcome. World J Surg (2004) 28(4):387-392.
6. Miller CA, Ellison EC: Therapeutic alternatives in metastatic neuroendocrine tumors. Surg Oncol Clin N Am (1998) 7(4):863-879.
7. Sippel RS, Carpenter JE, Kunnimalaiyaan M, Lagerholm S, Chen H: Raf-1 activation suppresses neuroendocrine marker and hormone levels in human gastrointestinal carcinoid cells. Am J Physiol Gastrointest Liver Physiol (2003) 285(2):G245-G254. • The intracellular signaling pathways that regulate production of bioactive molecules had not been completely understood prior to publication of these data. These results showed that Raf-1 induction suppresses neuroendocrine marker and hormone production in human gastrointestinal carcinoid cells via activation of a MEK-dependent pathway.
8. Kunninmalaiyaan M, Chen H: The Raf-1 pathway: A molecular target for treatment of select neuroendocrine tumors? Anticancer Drugs (2006) 17(2):139-142. • The researchers discussed the possibility that activation of the Ras/Raf signaling pathway may be a therapeutic target for patients with select NETs. In vitro activation of Raf-1 in NETs either by expression of the ectopic catalytic domain of Raf-1 or by a pharmacological drug (ZM-336372) resulted in growth inhibition and significant reduction in NE markers, such as serotonin, chromogranin A and calcitonin. These data support the development of Raf-1-activating compounds for the treatment of patients with NETs of selective subtypes.
9. Van Gompel JJ, Kunnimalaiyaan M, Holen K, Chen H: ZM-336372, a Raf-1 activator, suppresses growth and neuroendocrine hormone levels in carcinoid tumor cells. Mol Cancer Ther (2005) 4(6):910-917.
10. Kunnimalaiyaan M, Traeger K, Chen H: Conservation of the Notch1 signaling pathway in gastrointestinal carcinoid cells. Am J Physiol Gastrointest Liver Physiol (2005) 289(4):G636-G642.
11. Greenblatt DY, Cayo M, Ning L, Jaskula-Sztul R, Haymart M, Kunnimalaiyaan M, Chen H: Suberoyl bishydroxamic acid inhibits cellular proliferation by inducing cell cycle arrest in carcinoid cancer cells. J Gastrointest Surg (2007) 11(11):1515-1520.
12. Kunnimalaiyaan M, Ndiaye M, Chen H: Neuroendocrine tumor cell growth inhibition by ZM-336372 through alterations in multiple signaling pathways. Surgery (2007) 142(6):959-964. • This study highlights the role of GSK-3β in NE tumors.
13. Kadesch T: Notch signaling: The demise of elegant simplicity. Curr Opin Genet Dev (2004) 14(5):506-512.
14. Maillard I, Pear WS: Notch and cancer: Best to avoid the ups and downs. Cancer Cell (2003) 3(3):203-205.
15. Yoon K, Gaiano N: Notch signaling in the mammalian central nervous system: Insights from mouse mutants. Nat Neurosci (2005) 8(6):709-715.
16. Kunnimalaiyaan M, Chen H: Tumor suppressor role of Notch1 signaling in neuroendocrine tumors. Oncologist (2007) 12(5):535-542. • A thorough review of what is currently understood regarding Notch1 signaling in GI NETs.
17. Kunnimalaiyaan M, Haymart M, Chen H. Tumor suppressor role of Notch1 and Raf-1 signaling in medullary thyroid cancer cells. Translational Oncogenomics (2007) 2:43-47. • A review of the results of Notch1 and Raf-1 pathway activation in a medullary thyroid cancer cell line in vitro. These data clearly support the cell-context-dependent role of Notch1 and Raf-1 as either a tumor suppressor or a proto-oncogene.
18. Nakakura EK, Sriuranpong VR, Kunnimalaiyaan M, Hsiao EC, Schuebel KE, Borges MW, Jin N, Collins BJ, Nelkin BD, Chen H, Ball DW: Regulation of neuroendocrine differentiation in gastrointestinal carcinoid tumor cells by Notch signaling. J Clin Endocrinol Metab (2005) 90(7):4350- 4356.
19. Greenblatt DY, Vaccaro AM, Jaskula-Sztul R, Ning L, Haymart M, Kunnimalaiyaan M, Chen H: Valproic acid activates Notch1 signaling and regulates the neuroendocrine phenotype in carcinoid cancer cells. Oncologist (2007) 12(8):942-951.
20. Gallinari P, Di Marco S, Jones P, Pallaoro M, Steinkühler C: HDACs, histone deacetylation and gene transcription: From molecular biology to cancer therapeutics. Cell Res (2007) 17(3):195-211.
21. Stockhausen MT, Sjölund J, Manetopoulos C, Axelson H: Effects of the histone deacetylase inhibitor valproic acid on Notch signaling in human neuroblastoma cells. Br J Cancer (2005) 92(4):751-759.
22. Platta CS, Greenblatt DY, Kunnimalaiyaan M, Chen H: The HDAC inhibitor trichostatin A inhibits growth of small cell lung cancer cells. J Surg Res (2007) 142(2):219-226.
23. Ning L, Greenblatt DY, Kunnimalaiyaan M, Chen H: Suberoyl bis-hydroxamic acid activates Notch1 signaling and induces apoptosis in medullary thyroid carcinoma cells. Oncologist (2008) 13(2):98-104.
24. Kunnimalaiyaan M, Vaccaro AM, Ndiaye MA, Chen H: Inactivation of glycogen synthase kinase-3β, a downstream target of the Raf-1 pathway, is associated with growth suppression in medullary thyroid cancer cells. Mol Cancer Ther (2007) 6(3):1151-1158.
25. Younes N, Fulton N, Tanaka R, Wayne J, Straus FH 2nd, Kaplan EL: The presence of K-12 Ras mutations in duodenal adenocarcinomas and the absence of Ras mutations in other small bowel adenocarcinomas and carcinoid tumors. Cancer (1997) 79(9):1804-1808.
26. Paraskevakou H, Saetta A, Skandalis K, Tseleni S, Athanassiadis A, Davaris PS: Morphological-histochemical study of intestinal carcinoids and K-Ras mutation analysis in appendiceal carcinoids. Pathol Oncol Res (1999) 5(3):205-210.
27. Yashiro T, Fulton N, Hara H, Yasuda K, Montag A, Yashiro N, Straus F 2nd, Ito K, Aiyoshi Y, Kaplan EL: Comparison of mutations of Ras oncogene in human pancreatic exocrine and endocrine tumors. Surgery (1993) 114(4):758-763.
28. Hall-Jackson CA, Eyers PA, Cohen P, Goedert M, Boyle FT, Hewitt N, Plant H, Hedge P: Paradoxical activation of Raf by a novel Raf inhibitor. Chem Biol (1999) 6(8):559-568.
29. Hardt SE, Sadoshima J: Glycogen synthase kinase-3β: A novel regulator of cardiac hypertrophy and development. Circ Res (2002) 90(10):1055-63.
30. Harwood AJ, Plyte SE, Woodgett J, Strutt H, Kay RR: Glycogen synthase kinase 3 regulates cell fate in Dictyostelium. Cell (1995) 80(1):139-48.
31. Krylova O, Messenger MJ, Salinas PC: Dishevelled-1 regulates microtubule stability: A new function mediated by glycogen synthase kinase-3β. J Cell Biol (2000) 151(1):83-94.
32. Wang Q, Wang X, Hernandez A, Hellmich MR, Gatalica Z, Evers BM: Regulation of TRAIL expression by the phosphatidylinositol 3-kinase/Akt/GSK-3 pathway in human colon cancer cells. J Biol Chem (2002) 277(39):36602-36610.
33. Rowe MK, Weist C, Chuang D: GSK-3 is a viable potential target for therapeutic intervention in bipolar disorder. Neurosci Biobehav Rev (2007) 31(6):920-931.
34. Meares GP, Jope RS: Resolution of the nuclear localization mechanism of glycogen synthase kinase-3: Functional effects in apoptosis. J Biol Chem (2007) 282(23):16989-17001. • The known molecular mechanisms of GSK-3 are described in this study.
35. Fujimori M, Ikeda S, Shimizu Y, Okajima M, Asahara T: Accumulation of β-catenin protein and mutations in exon 3 of β-catenin in gastrointestinal carcinoid tumor. Cancer Res (2001) 61(18):6656-6659. • This study provided insight into the understanding of GI carcinoid tumors with respect to Wnt/β-catenin signaling.
36. Su MC, Wang CC, Chen CC, Hu RH, Wang TH, Kao HL, Jeng YM, Yuan RH: Nuclear translocation of β-catenin protein but absence of β-catenin and APC mutation in gastrointestinal carcinoid tumor. Ann Surg Oncol (2006) 13(12):1604-1609.
37. Kappes A, Vaccaro A, Kunnimalaiyaan M, Chen H: Lithium ions: A novel treatment for pheochromocytomas and paragangliomas. Surgery (2007) 141(2):161-165.
38. Tighe A, Ray-Sinha A, Staples OD, Taylor SS: GSK-3 inhibitors induce chromosome instability. BMC Cell Biol (2007) 8:34.
39. Luo J, Manning BD, Cantley LC: Targeting the PI3K-Akt pathway in human cancer: Rationale and promise. Cancer Cell (2003) 4(4):257-262. • This is an extensive review of early PI3K-Akt data describing multiple methods for interfering with pathway upregulation.
40. Kunnimalaiyaan M, Ndiaye M, Chen H: Apoptosis-mediated medullary thyroid cancer growth suppression by the PI3K inhibitor LY-294002. Surgery (2006) 140(6):1009-1015. • The potential role for PI3K-Akt pathway inhibition in GI NETs is strongly supported by the results of this study performed in MTC, a non-GI NET.
41. VioQuest Pharmaceuticals Inc: VioQuest Pharmaceuticals doses first patient in phase I/IIa clinical trial with VQD-002 (triciribine-phosphate) for treatment of leukemia. Press Release (2006): September 12.
42. Weisberg E, Banerji L, Wright RD, Barrett R, Ray A, Moreno D, Catley L, Jiang J, Hall-Meyers E, Sauveur-Michel M, Stone R et al: Potentiation of antileukemic therapies by the dual PI3K/PDK-1 inhibitor, BAG-956: Effects on BCR-ABL- and mutant FLT3-expressing cells. Blood (2008) 111(7):3723-3734.
43. NCT00501540: Lithium for low-grade neuroendocrine tumors. NIH, Bethesda, MD, USA (2008). http://clinicaltrials.gov/ct2/show/NCT00501540? term=lithium+carbonate&phase=1&rank=3.
44. NCT00113360: RAD-001 plus octreotide depot in metastatic or unresectable low grade neuroendocrine carcinoma. NIH, Bethesda, MD, USA (2008). http://clinicaltrials.gov/ct2/show/NCT00113360?term=RAD001&phase= 1&rank=14.
45. NCT00093782: CCI-779 in treating patients with progressive metastatic neuroendocrine tumors. NIH, Bethesda, MD, USA (2008). http:// clinicaltrials.gov/ct2/show/NCT00093782?term=CCI-779&phase=1&rank= 15.